Guardant Health Q4 Revenues Up 64 Percent

Mar 12, 2019

|

NEW YORK (GenomeWeb) – Guardant Health's stock surged in Wednesday morning trading after the company reported that its fourth quarter revenues rose 64 percent year over year, driven by a 98 percent increase in revenues from its precision oncology business.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Possible Effect of Border DNA Testing

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

Commission to Develop Report on Germline Editing

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

To Boost Productivity

The US Department of Agriculture presents a new blueprint for animal genomic research.

This Week in Genome Research

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.

Menu